| Dr Michael J Foggia, DO | |
|
1530 E Euclid Ave, Des Moines, IA 50313-4726 | |
| (515) 262-0404 | |
| (515) 262-0489 |
| Full Name | Dr Michael J Foggia |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 30 Years |
| Location | 1530 E Euclid Ave, Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417972084 | NPI | - | NPPES |
| 5N313 | Other | AR | AR BCBS |
| 158297003 | Medicaid | AR | |
| 200059120A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 03051 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Broadlawns Medical Center | Des moines, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Broadlawns Medical Center | 3678466166 | 207 |
News Archive
An analysis of race and ethnicity data from the TAILORx clinical trial was presented at the 2018 San Antonio Breast Cancer Symposium.
Health Spending In OECD Countries In 2004: An Update, by Gerard Anderson, Bianca Frogner, and Uwe Reinhardt. "In 2004, the U.S. health care system continued to provide less access to health care resources than the health systems in many other [industrialized] countries; however, the United States continued to have the highest level of spending," Anderson and coauthors report.
House lawmakers on Wednesday voted 420-3 to pass legislation (HR 493) that would ban discrimination against U.S. residents based on the results of genetic tests, CQ Today reports (Armstrong, CQ Today, 4/25).
Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.
CVS Caremark Corporation announced today the results of its previously announced solicitation of consents from the registered holders as of 5:00 p.m., New York City time on August 8, 2011 of its 6.125% Senior Notes due August 15, 2016 to terminate the replacement capital covenant, which was entered into on May 25, 2007, for the benefit of the holders of the Notes in connection with the issuance of its 6.302% Enhanced Capital Advantaged Preferred Securities due 2062.
› Verified 3 days ago
| Entity Name | Broadlawns Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467447508 PECOS PAC ID: 3678466166 Enrollment ID: O20040206000913 |
News Archive
An analysis of race and ethnicity data from the TAILORx clinical trial was presented at the 2018 San Antonio Breast Cancer Symposium.
Health Spending In OECD Countries In 2004: An Update, by Gerard Anderson, Bianca Frogner, and Uwe Reinhardt. "In 2004, the U.S. health care system continued to provide less access to health care resources than the health systems in many other [industrialized] countries; however, the United States continued to have the highest level of spending," Anderson and coauthors report.
House lawmakers on Wednesday voted 420-3 to pass legislation (HR 493) that would ban discrimination against U.S. residents based on the results of genetic tests, CQ Today reports (Armstrong, CQ Today, 4/25).
Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.
CVS Caremark Corporation announced today the results of its previously announced solicitation of consents from the registered holders as of 5:00 p.m., New York City time on August 8, 2011 of its 6.125% Senior Notes due August 15, 2016 to terminate the replacement capital covenant, which was entered into on May 25, 2007, for the benefit of the holders of the Notes in connection with the issuance of its 6.302% Enhanced Capital Advantaged Preferred Securities due 2062.
› Verified 3 days ago
| Entity Name | Ida County Iowa Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053327775 PECOS PAC ID: 9537070826 Enrollment ID: O20040323001795 |
News Archive
An analysis of race and ethnicity data from the TAILORx clinical trial was presented at the 2018 San Antonio Breast Cancer Symposium.
Health Spending In OECD Countries In 2004: An Update, by Gerard Anderson, Bianca Frogner, and Uwe Reinhardt. "In 2004, the U.S. health care system continued to provide less access to health care resources than the health systems in many other [industrialized] countries; however, the United States continued to have the highest level of spending," Anderson and coauthors report.
House lawmakers on Wednesday voted 420-3 to pass legislation (HR 493) that would ban discrimination against U.S. residents based on the results of genetic tests, CQ Today reports (Armstrong, CQ Today, 4/25).
Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.
CVS Caremark Corporation announced today the results of its previously announced solicitation of consents from the registered holders as of 5:00 p.m., New York City time on August 8, 2011 of its 6.125% Senior Notes due August 15, 2016 to terminate the replacement capital covenant, which was entered into on May 25, 2007, for the benefit of the holders of the Notes in connection with the issuance of its 6.302% Enhanced Capital Advantaged Preferred Securities due 2062.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael J Foggia, DO 1530 E Euclid Ave, Des Moines, IA 50313-4726 Ph: (515) 262-0404 | Dr Michael J Foggia, DO 1530 E Euclid Ave, Des Moines, IA 50313-4726 Ph: (515) 262-0404 |
News Archive
An analysis of race and ethnicity data from the TAILORx clinical trial was presented at the 2018 San Antonio Breast Cancer Symposium.
Health Spending In OECD Countries In 2004: An Update, by Gerard Anderson, Bianca Frogner, and Uwe Reinhardt. "In 2004, the U.S. health care system continued to provide less access to health care resources than the health systems in many other [industrialized] countries; however, the United States continued to have the highest level of spending," Anderson and coauthors report.
House lawmakers on Wednesday voted 420-3 to pass legislation (HR 493) that would ban discrimination against U.S. residents based on the results of genetic tests, CQ Today reports (Armstrong, CQ Today, 4/25).
Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.
CVS Caremark Corporation announced today the results of its previously announced solicitation of consents from the registered holders as of 5:00 p.m., New York City time on August 8, 2011 of its 6.125% Senior Notes due August 15, 2016 to terminate the replacement capital covenant, which was entered into on May 25, 2007, for the benefit of the holders of the Notes in connection with the issuance of its 6.302% Enhanced Capital Advantaged Preferred Securities due 2062.
› Verified 3 days ago
Neetha Molakala, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 University Ave, Suite 120, Des Moines, IA 50314 Phone: 515-248-1500 Fax: 515-248-1510 | |
Matthew Helmick Williams, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1801 Hickman Rd, Des Moines, IA 50314 Phone: 515-282-5640 Fax: 515-282-2332 | |
Todd Eberle, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-8678 Fax: 515-643-5802 | |
Evan Douglas Peterson, PA-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6520 Se 14th St, Des Moines, IA 50320 Phone: 515-953-1500 Fax: 515-953-2136 | |
April Winters, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2353 Se 14th St, Des Moines, IA 50320 Phone: 515-248-1400 Fax: 515-248-1414 | |
Kelli A Roenfanz, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 840 East University Avenue, Des Moines, IA 50316 Phone: 515-265-4211 Fax: 515-309-5993 | |
Dr. Sarah Sweeney Gude, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3509 E 29th St, Des Moines, IA 50317 Phone: 515-248-1600 Fax: 515-248-1610 |